from,to,evidence
PMC9119066,B.1.1.529,"Since the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages) (1)."
PMC9119066,B.1.617.2,"Since the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages) (1)."
PMC9119066,P.1,"Since the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages) (1)."
PMC9119066,B.1.1.7,"Since the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages) (1)."
PMC9119066,B.1.351,"Since the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages) (1)."
PMC9119066,Q.3,"Among the 732 clinical samples that were tested by both RT-qPCR and WGS, 43 samples (5.9%) were Alpha (B.1.1.7 or Q.3), 2 samples (0.3%) were Beta (B.1.351), 20 samples (2.7%) were Gamma (P.1 and sublineages), 378 samples (51.6%) were Delta (B.1.617.2 or AY sublineages), and 230 samples (31.4%) were Omicron (B.1.1.529 or BA sublineages)."
PMC9119066,B.1.621,"By WGS, these samples were variant of interest (VOI) Mu (B.1.621 or BB.2)."
PMC9088647,B.1.1.7,"This strain clade 201/501Y.V1, Pango lineage B.1.1.7, and GISAID clade are all recognized Alpha variant by various scientific names."
PMC9088647,B.1.351,"26
 There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246I, A701V, that have so far raised little concern."
PMC9088647,P.1,"56
 Safety and immunogenicity study of a SARS‐CoV‐2 variant vaccine (mRNA‐1273.351) is currently ongoing sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) (NCT04785144)..

Lineage P.1, frequently referred to as the gamma variant, is a cause of COVID‐19."
PMC9088647,P.2,Gamma variant is particularly found from the other Brazilian zeta variant (Lineage P.2).
PMC9088647,B.1.427,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA)."
PMC9088647,B.1.429,"These resembling variants, B.1.427 and B.1.429 (epsilon variant), were initially identified in California (USA)."
PMC9088647,B.1.617,"B.1.617.2 (Delta variant) is a variant of lineage B.1.617 of SARS‐CoV‐2, which is the reason for India's second wave in this pandemic of COVID‐19."
PMC9088647,B.1.617.1,"83
 The B.1.617.1 strain is 6.8‐fold more resistant to neutralization by sera from COVID‐19 convalescent and Moderna and Pfizer vaccinated patients, according to a live virus experiment."
PMC9088647,C.1.2,"92
 Researchers discovered that this new C.1.2 variant is evolving and mutating at a faster pace inside its genome than other VOC or VOI along with the Delta variant."
PMC9088647,B.1.1.529,"K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, and P681H are the most common spike protein mutations found in omicron variant.”
94
 According to preliminary laboratory findings, three doses of the Pfizer‐BioNTech COVID‐19 vaccine neutralize the Omicron variation (B.1.1.529 lineage), but two doses had much lower neutralization titers."
PMC9008484,B.1.621,"The three largest cities in Colombia: Bogotá, Medellín, and Cali, then witnessed increase in the weekly averages of cases and deaths by SARS-CoV-2, as well as a concerning presence of novel viral lineages: Alpha (B.1.1.7), Gamma (P.1), Delta (B.1.617.2), and Mu (B.1.621) (see text footnote 2) (3)..

Around the world, neither the onset of the pandemic, nor stringent lockdown protocols ever truly arrested the demonstration of public disagreement with modern social structures."
PMC9008484,B.1.617.2,"The three largest cities in Colombia: Bogotá, Medellín, and Cali, then witnessed increase in the weekly averages of cases and deaths by SARS-CoV-2, as well as a concerning presence of novel viral lineages: Alpha (B.1.1.7), Gamma (P.1), Delta (B.1.617.2), and Mu (B.1.621) (see text footnote 2) (3)..

Around the world, neither the onset of the pandemic, nor stringent lockdown protocols ever truly arrested the demonstration of public disagreement with modern social structures."
PMC9008484,P.1,"The three largest cities in Colombia: Bogotá, Medellín, and Cali, then witnessed increase in the weekly averages of cases and deaths by SARS-CoV-2, as well as a concerning presence of novel viral lineages: Alpha (B.1.1.7), Gamma (P.1), Delta (B.1.617.2), and Mu (B.1.621) (see text footnote 2) (3)..

Around the world, neither the onset of the pandemic, nor stringent lockdown protocols ever truly arrested the demonstration of public disagreement with modern social structures."
PMC9008484,B.1.1.7,"The three largest cities in Colombia: Bogotá, Medellín, and Cali, then witnessed increase in the weekly averages of cases and deaths by SARS-CoV-2, as well as a concerning presence of novel viral lineages: Alpha (B.1.1.7), Gamma (P.1), Delta (B.1.617.2), and Mu (B.1.621) (see text footnote 2) (3)..

Around the world, neither the onset of the pandemic, nor stringent lockdown protocols ever truly arrested the demonstration of public disagreement with modern social structures."
PMC9008484,B.1.1,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,A.2.5,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,B.1.625,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,B.1.1.348,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,C.37.1,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,C.37,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,B.1.1.487,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,B.1.621.1,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,P.1.10,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC9008484,B.1,"The figure shows the number of cases for SARS-CoV-2 reported daily and the value Rt calculated from 4 April 2021 to 31 July 2021, in the cites of Bogota (A) and Medellin (B)..

Based on the analysis of SARS-CoV-2 genome assemblies, available during the six evaluated sub-periods (4 April 2021 and 31 July 2021), we identified circulation of 16 SARS-CoV-2 lineages (with a lineage proportion of 50.44% lineage B.1.621, 24.12% C.37, 7.46% P.1, 4.39% B.1.1.348, 3.95% B.1.621.1, 2.63% B.1.1.7, 1.32% B.1, 0.88% lineages A.2.5, B.1.1, B.1.625, and B.1.623; and with a proportion of 0.44% the lineages AY.20, AY.26, B.1.1.487, C.37.1, and P.1.10), with the greatest diversity of lineages (9 lineages circulating) being represented in the first sub-period (between 4 April 04 2021 and 27 April 2021) when protests had yet not started."
PMC8902153,B.1.617.2,"We also look at the effectiveness of approved vaccines, antibody therapy and convalescent plasma on the currently prevalent VOCs, which are B.1.17, B.1.351, P.1, B.1.617.2 and B.1.1.529."
PMC8902153,P.1,"We also look at the effectiveness of approved vaccines, antibody therapy and convalescent plasma on the currently prevalent VOCs, which are B.1.17, B.1.351, P.1, B.1.617.2 and B.1.1.529."
PMC8902153,B.1.351,"We also look at the effectiveness of approved vaccines, antibody therapy and convalescent plasma on the currently prevalent VOCs, which are B.1.17, B.1.351, P.1, B.1.617.2 and B.1.1.529."
PMC8902153,B.1.1.529,"The D614G substitution is found in most of the circulating VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Gamma (P.1) and the recent delta plus (AY lineage) and Omicron (B.1.1.529) variants (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)."
PMC8902153,B.1.1.7,"The D614G substitution is found in most of the circulating VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Gamma (P.1) and the recent delta plus (AY lineage) and Omicron (B.1.1.529) variants (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)."
PMC8902153,B.1.617,"In addition, some of the notable substitutions in NTD are R246I (in B.1.351), W152C (in B.1.429), L18F (in B.1.351 and P.1), T19R (in B.1.17 and B.1.617) and G142D (in B.1.617 lineages), all of which are associated with immune-escape (17, 25, 26).."
PMC8902153,B.1.429,"In addition, some of the notable substitutions in NTD are R246I (in B.1.351), W152C (in B.1.429), L18F (in B.1.351 and P.1), T19R (in B.1.17 and B.1.617) and G142D (in B.1.617 lineages), all of which are associated with immune-escape (17, 25, 26).."
PMC8902153,B.1.1,"Fitness-enhancing mutations have been reported in nsp3, namely F206F, S1197R and T1198K, that has been associated with increased severity of infection for B.1.1 lineages (52)."
PMC8902153,B.1.617.1,"However, in-vitro neutralization assays show that casirivimab alone (without imdevimab) had reduced activity against (i) K417N+ E484K substitutions found in P.1 lineage (Brazil variant), and (ii) E484Q mutation expressed in B.1.617.1/B.1.617.3 lineages (Delta/Indian variants) (FDA) (74)."
PMC8902153,B.1.427,"According to the CDC, US, the P.1 variant seems more resistant to plasma therapy than B.1.351, B.1.617.2, B.1.427, B.1.429 and B1.1.7."
PPR452207,B.1.1.7,"Since the original strain of SARS-CoV-2 virus was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and Q."
PPR452207,B.1.617.2,"*), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and AY."
PPR452207,P.1,"*), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and AY."
PPR452207,B.1.351,"*), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and AY."
PPR452207,B.1.1.529,*) and Omicron (B.1.1.529 and BA.*).
PPR452207,Q.3,"Among the 732 clinical samples that were tested by both RT-qPCR and WGS, 43 samples (5.9%) were Alpha (B.1.1.7 or Q.3), 2 samples (0.3%) were Beta (B.1.351), 20 samples (2.7%) were Gamma (P.1 and sublineages), 378 samples (51.6%) were Delta (B.1.617.2 or AY."
PPR452207,B.1.621,"By WGS, these samples were variant of interest (VOI) Mu (B.1.621 or BB.2)."
PPR452207,B.1.1.519,"*), and Omicron (B.1.1.519 and BA."
PMC8942852,B.1.621,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,B.1.1.529,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,B.1.617.2,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,P.1,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,C.37,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,B.1.1.7,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,B.1.351,"As of December 2021, the World Health Organization (WHO) has defined five variants of concern (VOCs)—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages) and Omicron (originally B.1.1.529, then reclassified into BA lineages)—as well as two variants of interest, Lambda (C.37) and Mu (B.1.621)4."
PMC8942852,B.1.1,"On 24 November 2021, the B.1.1.529 lineage, a descendant of the SARS-CoV-2 B.1.1 lineage14, was reported to WHO as a novel variant spreading in South Africa15."
PMC8769358,B.1.427,"A total of 411 samples belonging to the Alpha 20I/501Y.V1 (B.1.1.7) strain of concern were identified, as well as one sample belonging to Beta 20H/501.V2 (B.1.351), thirteen belonging to Epsilon 20C/S:452R (B.1.427/B.1.429), two belonging to Delta 20A/S:478K (B.1.617.2), and 15 belonging to Gamma 20J/501Y.V3 (p.1)."
PMC8769358,B.1.617.2,"A total of 411 samples belonging to the Alpha 20I/501Y.V1 (B.1.1.7) strain of concern were identified, as well as one sample belonging to Beta 20H/501.V2 (B.1.351), thirteen belonging to Epsilon 20C/S:452R (B.1.427/B.1.429), two belonging to Delta 20A/S:478K (B.1.617.2), and 15 belonging to Gamma 20J/501Y.V3 (p.1)."
PMC8769358,P.1,"A total of 411 samples belonging to the Alpha 20I/501Y.V1 (B.1.1.7) strain of concern were identified, as well as one sample belonging to Beta 20H/501.V2 (B.1.351), thirteen belonging to Epsilon 20C/S:452R (B.1.427/B.1.429), two belonging to Delta 20A/S:478K (B.1.617.2), and 15 belonging to Gamma 20J/501Y.V3 (p.1)."
PMC8769358,B.1.1.7,"A total of 411 samples belonging to the Alpha 20I/501Y.V1 (B.1.1.7) strain of concern were identified, as well as one sample belonging to Beta 20H/501.V2 (B.1.351), thirteen belonging to Epsilon 20C/S:452R (B.1.427/B.1.429), two belonging to Delta 20A/S:478K (B.1.617.2), and 15 belonging to Gamma 20J/501Y.V3 (p.1)."
PMC8769358,B.1.351,"A total of 411 samples belonging to the Alpha 20I/501Y.V1 (B.1.1.7) strain of concern were identified, as well as one sample belonging to Beta 20H/501.V2 (B.1.351), thirteen belonging to Epsilon 20C/S:452R (B.1.427/B.1.429), two belonging to Delta 20A/S:478K (B.1.617.2), and 15 belonging to Gamma 20J/501Y.V3 (p.1)."
PMC8769358,B.1,"The second largest clade identified by Nextclade was the global 20C with 273 samples (19%); Pangolin categorized these into 31 unique lineages with most belonging to B.1, B.1.369, and B.1.311."
PMC8769358,B.1.369,"The second largest clade identified by Nextclade was the global 20C with 273 samples (19%); Pangolin categorized these into 31 unique lineages with most belonging to B.1, B.1.369, and B.1.311."
PMC8769358,B.1.2,"Pangolin classified most of these as the US strain B.1.2, except for 26 samples which were designated B.1.596."
PMC8769358,B.1.526,A clear trend can be observed with the average number of coding variants per sample increasing over time with a significant increase occurring near the end of March 2021 as highly mutated strains such as B.1.526 and B.1.1.7 became dominant.
PMC8769358,B.1.1,"While this mutation was observed in the B.1.1.7 and P.1 samples of this cohort, it was also seen in three B.1.621 samples, a B.1.1 sample, and a B.1.324 sample..

All coding variants observed in more than 1% of samples in the Delaware cohort are pictured."
PMC8769358,B.1.621,"While this mutation was observed in the B.1.1.7 and P.1 samples of this cohort, it was also seen in three B.1.621 samples, a B.1.1 sample, and a B.1.324 sample..

All coding variants observed in more than 1% of samples in the Delaware cohort are pictured."
PMC8769358,B.1.324,"While this mutation was observed in the B.1.1.7 and P.1 samples of this cohort, it was also seen in three B.1.621 samples, a B.1.1 sample, and a B.1.324 sample..

All coding variants observed in more than 1% of samples in the Delaware cohort are pictured."
PMC8769358,B.1.1.317,"The A845S spike mutation was observed at the same frequency as Q677H; while little is known about its effects, it has been proposed to aid in the transmissibility of the Russian B.1.1.317 strain [23]..

After normalizing for length, ORF8, ORF3, and the nucleocapsid ORF showed the greatest tolerance for mutations."
PPR442789,B.1.617.2,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta)."
PPR442789,P.1,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta)."
PPR442789,B.1.1.7,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta)."
PPR442789,B.1.351,"As a result of viral evolution, the initial SARS-CoV-2 genetic lineages identified early during the pandemic in Wuhan
5
, China, have been progressively replaced by several variants of concern (VOCs), such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1, (Gamma) and B.1.617.2 (Delta)."
PPR442789,B.1.1.529,"The most recent VOC, first identified in South Africa and named Omicron (B.1.1.529), is rapidly spreading worldwide
3
."
PPR442789,B.1.529,"Their neutralization spectrum is different and complementary, with NE12 being extremely potent against an early SARS-CoV-2 strain, WA-1, as well as against the B.1.1.7/Alpha and B.1.617.2/Delta variants, and NA8 exhibiting an unusually broad spectrum of action with ultrapotent activity against the two most challenging current VOCs, B.1.351/Beta and B.1.529/Omicron."
PPR442789,B.1.617,"Residues mutated in B.1.1.7, B.1.617 and B.1.351 (g, h) or B.1.1.529/Omicron (i, j) variants of concern are colored in magenta."
PMC8690919,B.1.1.7,"Although neutralization of one of these antibodies is abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7, B.1.351 and B.1.617.2.."
PMC8690919,B.1.351,"Although neutralization of one of these antibodies is abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7, B.1.351 and B.1.617.2.."
PMC8690919,B.1.617.2,"Finally, we investigate the effects of B.1.1.7, B.1.351 and B.1.617.2 variants of concern on the neutralization properties of these antibodies and explain these effects in terms of their structures..

A panel of plasmablast-derived anti-RBD antibodies efficiently neutralized the SARS-CoV-2 pseudovirus and live virus 14 (Figure 1A) and targeted non-overlapping epitope groups (Figure S1)."
PMC8690919,P.1,"Similar histopathological findings of lung and trachea were observed in the therapeutic experiment (Figure 5D, Tables S1 and S2)..

Taken together, the Syrian hamster study shows that the prophylactic or therapeutic treatment with either 40 or 4 mg/kg of antibody cocktail could significantly reduce lung viral load and attenuate SARS-COV-2 virus-induced pulmonary inflammation as judged by histopathological examination..

Several new variants have emerged since late 2020, i.e., the B.1.1.7, B.1.351, P.1, B.1.617.2 lineages, and G614 polymorphism."
PMC8754802,P.1,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,P.3,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.351,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.621,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.617.1,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.525,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.617.2,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.526,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,C.37,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.1.7,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,P.2,"Furthermore, among these lineages, WHO identified, based on transmissibility, pathogenicity and the impact on vaccines, several SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), and variants of interest (VOIs), including Epsilon (B.1.429 + B.1.427), Zeta (P.2), Eta (B.1.525), Theta (P.3), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and Mu (B.1.621).."
PMC8754802,B.1.214.2,"For the rest of lineages, we identified indel types in S, namely RDT-S-4, pos_22205+9, and pos_22206+9, within B.1.36, B.1.214.2, and A.2.5, respectively."
PMC8754802,A.2.5,"For the rest of lineages, we identified indel types in S, namely RDT-S-4, pos_22205+9, and pos_22206+9, within B.1.36, B.1.214.2, and A.2.5, respectively."
PMC8754802,B.1.36,"For the rest of lineages, we identified indel types in S, namely RDT-S-4, pos_22205+9, and pos_22206+9, within B.1.36, B.1.214.2, and A.2.5, respectively."
PMC8707919,B.1.617.2,"The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve."
PMC8707919,B.1.617.1,"The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve."
PMC8707919,B.1.617,"The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but the Delta variants have become dominant worldwide and continue to evolve."
PMC8707919,P.1,"In comparison, similar modest reductions were also observed for C.37, P.1, R.1, and B.1.526 pseudoviruses, but 7- and 16-fold reductions for vaccine-elicited and convalescent sera, respectively, were seen for B.1.351 pseudoviruses."
PMC8707919,B.1.526,"In comparison, similar modest reductions were also observed for C.37, P.1, R.1, and B.1.526 pseudoviruses, but 7- and 16-fold reductions for vaccine-elicited and convalescent sera, respectively, were seen for B.1.351 pseudoviruses."
PMC8707919,C.37,"In comparison, similar modest reductions were also observed for C.37, P.1, R.1, and B.1.526 pseudoviruses, but 7- and 16-fold reductions for vaccine-elicited and convalescent sera, respectively, were seen for B.1.351 pseudoviruses."
PMC8707919,R.1,"In comparison, similar modest reductions were also observed for C.37, P.1, R.1, and B.1.526 pseudoviruses, but 7- and 16-fold reductions for vaccine-elicited and convalescent sera, respectively, were seen for B.1.351 pseudoviruses."
PMC8707919,B.1.351,"In comparison, similar modest reductions were also observed for C.37, P.1, R.1, and B.1.526 pseudoviruses, but 7- and 16-fold reductions for vaccine-elicited and convalescent sera, respectively, were seen for B.1.351 pseudoviruses."
PMC8707919,B.1,"One of the earliest variants that is highly infectious and thus became globally dominant is B.1 (D614G) [8,9,10,11]."
PMC8707919,B.1.429,"Subsequent genomic surveillance has led to the identification of several convergently evolving lineages, including in UK—B.1.1.7 (Alpha), South Africa—B.1.351 (Beta), Brazil/Japan—P.1 (Gamma), California, USA—B.1.427/B.1.429 (Epsilon), Northeast USA—B.1.526 (Iota), USA/Japan—(R.1), Peru/Chile—C.37 (Lambda), and Liverpool—A.23.1."
PMC8707919,B.1.427,The B.1.427/B.1.429 and B.1.617 lineage variants share the L452R substitution in RBD [23].
PMC8707919,P.3,"The E484K substitution found in B.1.351, B.1.526, P.1, P.3 (theta), and some B.1.617 variants confers some level of resistance to neutralization by convalescent sera, vaccine-elicited sera, and therapeutic neutralizing antibodies [16]."
PMC8707919,B.1.1.7,These findings extend a prior study reporting that spike-binding titers in convalescent sera from unvaccinated persons were decreased 4- to 6-fold for B.1.617.2 when compared to B.1.1.7 and WT(D614G) [41].
PMC8707919,B.1.2,"Furthermore, continued surveillance is necessary as several independent lineages have recently emerged containing additional substitutions proximal to S1/S2 cleavage junction, such as the B.1.2 and B.1.525 with Q677H, C.37 and B.1.617.2 with Q675H, and C.1.2 with N679K substitutions [62,63]."
PMC8707919,C.1.2,"Furthermore, continued surveillance is necessary as several independent lineages have recently emerged containing additional substitutions proximal to S1/S2 cleavage junction, such as the B.1.2 and B.1.525 with Q677H, C.37 and B.1.617.2 with Q675H, and C.1.2 with N679K substitutions [62,63]."
PMC8707919,B.1.525,"Furthermore, continued surveillance is necessary as several independent lineages have recently emerged containing additional substitutions proximal to S1/S2 cleavage junction, such as the B.1.2 and B.1.525 with Q677H, C.37 and B.1.617.2 with Q675H, and C.1.2 with N679K substitutions [62,63]."
PMC8707919,B.1.617.3,"Sequences corresponding to the S1/S2 region of SARS-CoV-2 B.1.1.7 (EPI_ISL_1374509), B.1.617.1 (EPI_ISL_1841346), B.1.617.2 (EPI_ISL_2229775), B.1.617.3 (EPI_ISL_2157058), Bat CoV RmYN02 (EPI_ISL_412977), as well as HA of Influenza A virus (A/California/04/pdm09 (H1N1)) (EPI1859607) were obtained from GISAID..

To quantify whether higher ACE2 binding and furin cleavage of B.1.617.2 spike augments fusion between virus and/or cell membranes, we performed cell-cell fusion assays by complementing β-galactosidase subunits in spike-transfected effector cells and 293T-ACE2.TMPRSS2 target cells."
PPR428671,P.1,"Genomic surveillance of SC2 variants has been imperative to inform the public health response regarding the use of clinical therapies in specific jurisdictions based on the proportion of particular variants (e.g., Gamma (P.1)) in a region."
PPR428671,A.2.5,"Here, we describe the introduction of SC2 lineage A.2.5 in Florida, which contains S:L452R (a substitution of therapeutic concern) and two novel Spike INDELS, the deletion of 141-143 and ins215AGY, with unknown implications on immune response."
PPR428671,A.2.4,"In January 2021, BPHL detected the first cases of then SC2 lineage A.2.4 among an outbreak at a south Florida healthcare facility."
PPR428671,B.1,"The A.2.5 lineage in Florida became of particular interest due to the presence of mutations in the spike protein, associated with VOCs, including convergent evolution of D614G, a defining mutation among B.1 Pango lineages (31, 32), initially found in clades predominantly in Europe (33, 34)."
PPR428671,B.1.427,"A.2.5 also contains spike L452R, a CDC-defined SOTC (10), predominantly observed in Epsilon (B.1.427/B.1.429), which emerged in southern California in May 2020 and exhibits 20% increased transmissibility (4)."
PPR428671,B.1.617.2,"Allele L452R has independently emerged in several other lineages over the last several months, including Iota (B.1.526), Kappa (B.1.617.1), Delta (B.1.617.2), and C.36 (10)."
PPR428671,B.1.526,"Allele L452R has independently emerged in several other lineages over the last several months, including Iota (B.1.526), Kappa (B.1.617.1), Delta (B.1.617.2), and C.36 (10)."
PPR428671,B.1.617.1,"Allele L452R has independently emerged in several other lineages over the last several months, including Iota (B.1.526), Kappa (B.1.617.1), Delta (B.1.617.2), and C.36 (10)."
PPR428671,C.36,"Allele L452R has independently emerged in several other lineages over the last several months, including Iota (B.1.526), Kappa (B.1.617.1), Delta (B.1.617.2), and C.36 (10)."
PPR428671,B.1.1.7,"Additional mutations causing increased transmissibility are likely key factors in why variants, such as Alpha (B.1.1.7) and Delta (B.1.671.2), have significant case counts around the world and soon became the dominant variant in geographical areas, such as the U.S., India, and the U.K. shortly after they emerged (1, 11, 44, 45)."
PMC8635972,B.1.1.7,The alpha/B.1.1.7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 cases in many European countries.
PMC8635972,P.1,"The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains."
PMC8635972,B.1.351,"The incidence domination was likely due to a fitness advantage that could be driven by the receptor-binding domain (RBD) residue change (N501Y), which also emerged independently in other variants of concern such as the beta/B.1.351 and gamma/P.1 strains."
PMC8635972,B.1.621,"Some of these residue substitutions, including the N501Y mutation, seem to have arisen independently by convergent evolution and selection and are found in the B.1.1.7 (alpha), the South African B.1.351 (beta), and the Brazilian P.1 (gamma) variants of concern (VOC) (Rambaut, 2020; Faria et al., 2021; Tegally et al., 2021) as well as the variant of interest (VOI) B.1.621 (mu), first identified in Colombia (Laiton-Donato et al., 2021), and the former VOI P.3 (theta) from The Philippines (Tablizo et al., 2021)."
PMC8635972,P.3,"Some of these residue substitutions, including the N501Y mutation, seem to have arisen independently by convergent evolution and selection and are found in the B.1.1.7 (alpha), the South African B.1.351 (beta), and the Brazilian P.1 (gamma) variants of concern (VOC) (Rambaut, 2020; Faria et al., 2021; Tegally et al., 2021) as well as the variant of interest (VOI) B.1.621 (mu), first identified in Colombia (Laiton-Donato et al., 2021), and the former VOI P.3 (theta) from The Philippines (Tablizo et al., 2021)."
PMC8635972,B.1.617.2,"All the above VOC/VOI have been for the most part replaced by the B.1.617.2 (delta), which emerged in India in December 2020 (Cherian et al., 2021; Yadav, 2021) and has become the dominant variant globally (http://www.gisaid.org/, accessed October 2021)."
PMC8635972,B.1,"In order to examine whether the increased affinity of the N501Y variant for ACE-2 was associated with a more efficient establishment of infection and development of disease, we challenged transgenic ACE-2 humanized K18-hACE2 mice with the early 2020 SARS-CoV2 B.1 (Freiburg isolate, FR-4248 Miladi, 2020) and the B1.1.7 (alpha) strains."
PMC8646660,B.1.1.7,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
PMC8646660,B.1.617.2,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
PMC8646660,P.1,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
PMC8646660,B.1.351,"FD20 engages the RBD at an epitope distal to the RBM with a K
D of 5.6 nM, neutralizes SARS‐CoV‐2 including the current Variants of Concern such as B.1.1.7, B.1.351, P.1, and B.1.617.2 (Delta), displays modest cross‐reactivity against SARS‐CoV, and reduces viral replication in hamsters."
PMC8646660,B.1.1.298,"Y453F increases the ACE2 binding affinity, and with A475V and F490L, is found in independent mink‐related SARS‐CoV‐2 variants (Larsen et al, 2021; Oude Munnink et al, 2021) identified in Denmark and the Netherlands (B1.1 and B.1.1.298) that may escape human antisera and REG10933 (Starr et al, 2021)."
PMC8646660,B.1.177,"A222V and S477N are described in 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) that emerged in early summer 2020 and subsequently spread to multiple locations in Europe at the end of 2020 (Lemey et al, 2021)."
PMC8646660,B.1.160,"A222V and S477N are described in 20A.EU1 (B.1.177) and 20A.EU2 (B.1.160) that emerged in early summer 2020 and subsequently spread to multiple locations in Europe at the end of 2020 (Lemey et al, 2021)."
PMC8646660,B.1.141,"N439K is in B.1.141, B.1.258, and in mink strains; it increases affinity to ACE2 and reduces neutralization of sera from convalescent patients (Thomson et al, 2021)."
PMC8646660,B.1.258,"N439K is in B.1.141, B.1.258, and in mink strains; it increases affinity to ACE2 and reduces neutralization of sera from convalescent patients (Thomson et al, 2021)."
PMC8602852,B.1.621,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics."
PMC8602852,B.1.617.2,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics."
PMC8602852,P.1,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics."
PMC8602852,C.37,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics."
PMC8602852,B.1.1.7,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics."
PMC8602852,B.1.351,"Four SARS-CoV-2 variants of concern including B.1.1.7, B.1.351, B.1.617.2, and P.1, and two variants of interest including C.37 and B.1.621 have been reported to have potential immune escape, and one or more mutations endow them with worrisome epidemiologic, immunologic, or pathogenic characteristics."
PMC8602852,B.1.619,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.214.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.427,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.526,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.466.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.620,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.1.523,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.1.318,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.1.519,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.617.1,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,R.1,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,C.1.2,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,B.1.525,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,C.36.3,"Currently designated VUMs include B.1.427/B.1.429 (first detected in California, USA), R.1 (first detected in several countries in January 2021), B.1.466.2 (first detected in Indonesia), B.1.1.318 (detected in multiple countries in January 2021), B.1.1.519 (detected in several countries in January 2021), C.36.3 (detected in several countries in January 2021), B.1.214.2 (detected in several countries in November 2020), B.1.1.523 (detected in several countries in May 2020), B.1.619 (detected in several countries in May 2020), B.1.620 (detected in several countries in November 2020), C.1.2 (first detected in South Africa), B.1.525 (Eta, detected in several countries in December 2020), B.1.526 (Iota, first detected in the United States), and B.1.617.1 (Kappa, first detected in India) [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/]."
PMC8602852,P.3,"Some former VOIs but no longer designated as VUMs include P.2 (first detected in Brazil) and P.3 (first detected in the Philippines) (
Supplementary Figures 1
, 
2
) [Variants: distribution of cases data, 20 May 2021-GOV.UK (www.gov.uk)].."
PMC8602852,P.2,"Some former VOIs but no longer designated as VUMs include P.2 (first detected in Brazil) and P.3 (first detected in the Philippines) (
Supplementary Figures 1
, 
2
) [Variants: distribution of cases data, 20 May 2021-GOV.UK (www.gov.uk)].."
PMC8602852,B.1.1.28,"P.3 as well as P.1 belong to B.1.1.28 lineage (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)..

With increased infectivity and virulence, a new variant with an L452R mutation in S protein appeared in California in March 2020, which was named B.1.427/429."
PMC8602852,B.1.617,"At the same time, B.1.525 was resistant to neutralization of convalescent serum, vaccine-elicited serum, and monoclonal antibodies (44)..

As of September 26, 2021, India’s confirmed cases in has reached 33,652,745, becoming the country with the second largest cumulative number of confirmed cases in the world, which was propelled by variant B.1.617 [https://coronavirus.jhu.edu/map.html]."
PMC8602852,B.1.617.3,"With the spread of the local epidemic in India, B.1.617.1, B.1.617.2, and B.1.617.3 strains emerged successively."
PMC8598544,B.1.617.2,"The Delta (B.1.617.2) variant was first identified in October 2020 in Maharashtra, India and was classified as a VOC in May 2021 by WHO."
PMC8598544,C.37,"The Lambda variant belongs to the C.37 lineage and classified as a VOI on June 14, 2021 by the WHO."
PMC8598544,B.1.621,"On August 30, 2021, the WHO announced the Mu variant (B.1.621) and classified it as a VOI (8,45), which has mutations associated with potential immune escape."
PMC8535385,B.1.617.2,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176]."
PMC8535385,P.1,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176]."
PMC8535385,B.1.1.7,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176]."
PMC8535385,B.1.351,"The new variants are accumulating mutations in different spike domains, such as the alpha variant or B.1.1.7 lineage (also known as 501Y.V1 or VOC202012/01), the beta variant or B.1.351 lineage (501Y.V2), the gamma variant or P.1 lineage (501Y.V3) and the delta variant or B.1.617.2 lineage [176]."
PMC8501352,B.1.117,At the time of the first clinical trials the “original” virus was gradually replaced by the alpha variant (B.1.117) and at the moment almost all cases e.g.
PMC8525575,B.1.427,"The massive emergence of L452R variants was first linked to lineage B.1.427/B.1.429 (clade 21C) that has been spreading in California since November and December 2020, originally named CAL.20C and currently variant of interest epsilon."
PMC8525575,B.1.232,"By PCR amplification and Sanger sequencing of a 541-base fragment coding for amino acids 414 to 583 of the RBD from a collection of clinical specimens, we identified a separate L452R variant that also recently emerged in California but derives from the lineage B.1.232, clade 20A (named CAL.20A)."
PMC8525575,B.1.1.28,"Because of the important functional and antigenic properties of the RBD, structural changes in this domain deserve special attention and have already been highlighted by such notorious RBD mutations as E484K (e.g., found in B.1.1.28, also known as the “Brazil” variant or VOI zeta) and N501Y (found in B.1.1.7, also known as the “British” variant or VOC alpha, and in B.1.351, also known as the “South African” variant or VOC beta) (4)..

We evaluated the feasibility of determining mutational changes in the S1 region by PCR amplification of a 541-base fragment within and immediately downstream from the RBD coding region (see Materials and Methods)."
PMC8525575,B.1.1.7,"Because of the important functional and antigenic properties of the RBD, structural changes in this domain deserve special attention and have already been highlighted by such notorious RBD mutations as E484K (e.g., found in B.1.1.28, also known as the “Brazil” variant or VOI zeta) and N501Y (found in B.1.1.7, also known as the “British” variant or VOC alpha, and in B.1.351, also known as the “South African” variant or VOC beta) (4)..

We evaluated the feasibility of determining mutational changes in the S1 region by PCR amplification of a 541-base fragment within and immediately downstream from the RBD coding region (see Materials and Methods)."
PMC8525575,B.1.351,"Because of the important functional and antigenic properties of the RBD, structural changes in this domain deserve special attention and have already been highlighted by such notorious RBD mutations as E484K (e.g., found in B.1.1.28, also known as the “Brazil” variant or VOI zeta) and N501Y (found in B.1.1.7, also known as the “British” variant or VOC alpha, and in B.1.351, also known as the “South African” variant or VOC beta) (4)..

We evaluated the feasibility of determining mutational changes in the S1 region by PCR amplification of a 541-base fragment within and immediately downstream from the RBD coding region (see Materials and Methods)."
PMC8525575,A.27,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.617.3,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.1.263,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.36,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,A.21,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.466,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.1.459,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.526.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,A.2.5.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,A.2.5.2,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.617.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.429,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.177.83,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,C.36.1,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,B.1.617.2,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,P.4,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,C.37,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,C.16,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PMC8525575,C.36.3,"A.2.5, A.2.5.1, A.2.5.2, A.21, A.27, B.1.1.263, B.1.1.459, B.1.36, B.1.177.83, B.1.232, B.1.351, B.1.427, B.1.429, B.1.466, B.1.526.1, B.1.617.1, B.1.617.2, B.1.617.3, C.16, C.36.1, C.36.3, C.37, and P.4 were downloaded from the GISAID database (https://www.gisaid.org/, as of 12 June 2021) (see Table S4)."
PPR380399,P.1,"In late 2020, three SARS-CoV-2 variants of concern (VOC); B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), rapidly spread due to enhanced transmission rates and have since been linked to increased hospitalizations and mortalities [1–9]."
PPR380399,B.1.1.7,"In late 2020, three SARS-CoV-2 variants of concern (VOC); B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), rapidly spread due to enhanced transmission rates and have since been linked to increased hospitalizations and mortalities [1–9]."
PPR380399,B.1.351,"In late 2020, three SARS-CoV-2 variants of concern (VOC); B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma), rapidly spread due to enhanced transmission rates and have since been linked to increased hospitalizations and mortalities [1–9]."
PPR380399,B.1.427,"In early 2021, several new VOC appeared including, B.1.617 (Delta), B.1.427 (Epsilon), and B.1.526 (Iota)."
PPR380399,B.1.526,"In early 2021, several new VOC appeared including, B.1.617 (Delta), B.1.427 (Epsilon), and B.1.526 (Iota)."
PPR380399,B.1.617,"In early 2021, several new VOC appeared including, B.1.617 (Delta), B.1.427 (Epsilon), and B.1.526 (Iota)."
PPR380399,D.2,"The D.2 variant in Australia was defined by an initial I120F substitution in nsp2 followed by S477N in S, which led to its rapid expansion."
PPR380399,B.1.160,"In contrast, B.1.160, which carries S S477N solely, did not rapidly expand."
PPR380399,B.1.429,"The substitution D260Y, present in B.1.427 and B.1.429, is located at the entrance of the NTPase active site and may favor π-π stacking interactions with nucleobases (Figure 6e-f)."
PPR380399,B.1.177,"Several lineages show introgression from others (e.g., cyan nodes, B.1.160, into brick red, B.1.177)."
PPR380399,B.1,c. Population-level analysis of new mutations per day (accounting for multiple mutations per site) displays a declining rate of mutations after the emergence of B.1 (S D614G and nsp12 P323L).
PMC7705438,V.2,Variants with minor allele frequency less than 0.005 as per GnomAD v.2 were filtered and those located in genes known to be associated with cataract development as per Cat-Map database were given a priority for further evaluation.
PMC7705438,C.14,"We identified one previously reported (c.2729 C>T), five novel missense (c.3029 A>G, c.1738-1739 del ins TT, c.1163 G>A, c.3058 C>T, c.329 G>A) and two novel nonsense (c.1213 delT fs*, c.14 C>A fs*) mutations."
PMC7705438,V.1,"All variants were reclassified according to ACMG/AMP guidelines (both applying the TP53 rule specifications (v.1) provided by the ClinGen TP53 Expert Panel, and automatically using PathoMan).."
PMC7705438,C.38,"Results: We found 8 mutations in this patient in 2018 when he found the cancer and the mutation sites were APC c.3189 delT (50.81%), TP53 c.339 delC (55.46%), KRAS c.38 G>A (39.38%), EYS c.157 T>G (0.38%), KIT c.147 C>T (0.31%), PHACTR1 c.760 C>G (0.20%), CSMD3 c.837 T>G (0.08%) and SLITRK4 c.329 A>C (0.05%)."
